Innate Pharma Reports Full Year 2025 Financial Results and Business Update
Innate Pharma S.A. - American Depositary Shares (IPHA)
Company Research
Source: Business Wire
Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty structuresIPH4502 (Nectin-4 ADC) shows preliminary anti-tumor activity with favorable safety profile to date; Phase 1 cohort enrichment ongoing at active dose levelsMonalizumab PACIFIC-9 Phase 3 trial, partnered with AstraZeneca, continues to advance toward a planned H2 2026 data readoutIPH5201 (anti-CD39 antibody), partnered with AstraZeneca - Interim results of MATISSE Phase 2 trial in non-small cell lung cancer (NSCLC) have been selected for an oral presentation in one of the Clinical Trials Plenary Session Sessions at the AACR Annual Meeting 2026, on April 21Cash position of €44.8 million1 as of December 31, 2025 with an anticipated cash runway until the end of Q3 2026Conference call to be held today at 2:00 p.m. CET / 9:00 a.m. EDT MARSEILLE, Franc
Show less
Read more
Impact Snapshot
Event Time:
IPHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPHA alerts
High impacting Innate Pharma S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IPHA
News
- Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Innate Pharma GAAP EPS of -€0.55, revenue of €9.01M [Seeking Alpha]Seeking Alpha
- Innate Pharma Reports Full Year 2025 Financial Results and Business Update [Yahoo! Finance]Yahoo! Finance
- Innate Pharma (IPHA) was upgraded by BTIG Research to "strong-buy".MarketBeat
- Innate Pharma (IPHA) had its "buy" rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.MarketBeat